1. Abad CC, Guilleminault C. Insomnia in elderly patients: re commendations for pharmacological management. Drugs Aging 2018; 35: 791-817.
2.
Ancoli-Israel S, Krystal AD, McCall WV, Schaefer K, Wilson A, Claus R et al. A 12-week, randomized, double-blind, pla cebo-controlled study evaluating the effect of eszopiklone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep 2010; 33: 225-234.
3.
Bastien CH, Vallieres A, Morin CM. Validation of the In somnia Severity Index as an outcome measure for insomnia research. Slepp 2001; 2: 297-307.
4.
Bieńkowski P, Samochowiec J, Sienkiewicz-Jarosz H, Wich niak A, Mastalerz-Migas A. Bezpieczne stosowanie benzo diazepin w podstawowej opiece zdrowotnej – rekomendacje dla lekarzy rodzinnych. Lekarz POZ 2019; 3-4: 177-193.
5.
Brielmaier BD. Eszopiclone (Lunesta): a new nonbenmzodi azepine hypnotic agent. Pharmacol. Notres. 2006; 19: 54-59
6.
Erman MK, Zammit G, Rubens R, Schaefer K, Werssel T, Am ato D et al. A polysomnographic placebo-controlled evalu ation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia. J Clin Sleep Med 2008; 4: 229-234.
7.
Eszopiclone for insomnia. Cohrane Database Syst Rev 2018; 10. 8. Fornal-Pawłowska M, Wołyńczyk-Gmaj D, Szelenberger W. Walidacja Ateńskiej Skali Bezsenności. Psychiatria Pol 2011; 45: 211-221.
8.
Kesselheim AS, Sinha MS, Rausch P, Lu Z, Tessema FA, Lap pin BM et al. Patient’s knowledge of key messaging in Drug Safety Communications for zolpidem and eszopiclone: a na tional survey. J Law Med Ethics 2019; 47: 430-441.
9.
Kirkwood C, Breden E. Management of insomnia in elderly patients using eszopiclone. Nat Science Sleep 2010; 2: 151-158.
10.
Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC et al. Sustained efficacy of eszopiklone over 6 month of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003; 26: 793-799.
11.
Krystal AD, McCall WVB, Fava M, Joffe H, Soares CN, Huang H et al. Eszopiclone treatment for insomnia: effect size com parisons in patients with primary insomnia and insomnia with medical and psychiatric comorbidity. Prim Care Com panion CNS Disord 2010; 14: 4.
12.
Kuntz JL, Kouch L, Christian D, Peterson PL. Patient educa tion and pharmacist consultation influence on nonbenzodi azepine sedative medication deprescribing success for older adults. Perm J 2019; 23: 16-18
13.
Liang L, Huang Y, Xu R, Wei Y, Xiao L, Wang G. Eszopiclone for the treatment of primary insomnia: a systematic review and meta-analysis of double-blind, randomized, place bo-controlled trials. Sleep Med 2019; 62: 6-13.
14.
Lindberg E, Janson C, Johannessen A, Svanes C, Real FG, Ma linovschi A et al. Sleep Med 2020; 69: 8-13.
15.
Matheson E, Hainer BL. Insomnia: pharmacologic therapy. Am Fam Phys 2017; 96: 29-35.
16.
McCall WV, Erman M, Krystal AD, Rosenb erg R, Scharf M, Zammit GK et al. A polysomnographic study of eszopiklone in elderly patients with insomnia. Curr Med Res Opin 2006; 22: 1633-1642.
17.
Nigam G, Camacho M, Riaz M. The effect of nonbenzodiaz epines sedative hypnotics on apnea-hypopnea index: a me ta-analysis. Am Thorac Med 2019; 14: 49-554.
18.
Oliveira P, Coroa M, Madeira N. Treatment options for in somnia in schizophrenia: a systematic review. Pharmacopsy chiatry 2019; 52: 165-169.
19.
Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med 2016; 165(1539-3704 (Electro nic): 125-33.
20.
Pinto LR, Bittencourt LR, Treptow EC, Braga LR, Tufik S: Eszopiclone versus zopiclone in the treatment of insomnia. Clinics (San Paolo) 2016; 71: 5-9.
21.
Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res 2017; 26: 675-700.
22.
Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults. An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med 2017; 13: 307-49.
23.
Scharf M, Erman M, Rosenberg R, Seiden D, McCallWV, Amato D et al. A 2-week efficacy and safety study of eszopiklone in eld erly patients with primary insomnia. Sleep 2005; 28: 720-727.
24.
Siemiński M, Skorupa Ł, Wiśniewska-Skorupa K. Diagno styka i terapia bezsenności w praktyce ogólnolekarskiej. Forum Medycyny Rodzinnej 2018; 12: 242-251
25.
Szelenberger W, Skalski M. Zaburzenia snu. In: Pużyński S, Rybakowski J, Wciórka J (red.). Psychiatria, t. 2, Elsevier Urban & partner, Wrocław, 2011: 501-505.
26.
Takahashi J, Kanbayashi T, Ito Uemura S, Sagawa Y, Tsutsui K, Takahashi Y et al. Residual effects of eszepiclone and pla cebo in healthy elderly subjects: a randomized double-blind trial. Sleep Biol Rhythms 2018; 15: 235-241.
27.
Walsh JK, Krystal AD, Amato DA, Rubens R, Caron J, Wessel TC et al. Nightly treatment of primary insomnia with eszo piclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007; 30: 959-967.
28.
Wichniak A. Standardy leczenia farmakologicznego wybra nych zaburzeń snu. In: Jarema M (red.). Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. Via Medica, Gdańsk 2015: 224-249.
29.
Wichniak A, Jarema M. Podstawy rozpoznawania i leczenia wybranych zaburzeń snu. Biblioteka czasopisma „Psychia tria”, ViaMedica, Gdańsk 2018.
30.
Wichniak A, Wierzbicka A, Gustavsson K, Szmyd J, Jernajczyk W. Melatonina w leczeniu zaburzeń rytmu okołodobo wego snu i czuwania – zasady wyboru właściwej pory przyję cia i dawki. Farmakoter Psychiatr Neurol 2018; 34: 263–283.
31.
Wilt TJ, MacDonald R, Brasure M, Olson CM, Carlyle M, Fuchs E et al. Pharmacologic treatment of insomnia disorder: an evidence report for a clinical practice guideline by the American College of Physicians. Ann Intern Med 2016; 165: 193-112.
32.
Yoshida M, Kojima H, Uda A, Haraguchi T, Ozeki M, Kawasa ki I et al. Bitterness-masking effects of different beverages on zopiclone and eszopiklone tablets. Che Pharm Bull (Tokyo) 2019; 67: 404-409.
33.
Zammit GK, McNab LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiklone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004; 20: 1979-1991.
